Intelligent Bio Solutions Inc. (NASDAQ:INBS) Short Interest Down 5.1% in January

Intelligent Bio Solutions Inc. (NASDAQ:INBS) saw a large decline in short interest during the month of January. As of January 15th, there was short interest totalling 427,400 shares, a decline of 5.1% from the December 31st total of 450,500 shares. Approximately 9.1% of the company’s shares are sold short. Based on an average trading volume of 118,600 shares, the short-interest ratio is currently 3.6 days.

Intelligent Bio Solutions Stock Down 0.6 %

Shares of Intelligent Bio Solutions stock traded down $0.01 during trading on Monday, hitting $1.75. 324,738 shares of the stock were exchanged, compared to its average volume of 128,868. Intelligent Bio Solutions has a 12 month low of $1.00 and a 12 month high of $11.70. The stock’s fifty day moving average is $1.47 and its 200 day moving average is $1.49.

Intelligent Bio Solutions (NASDAQ:INBS) last posted its quarterly earnings results on Thursday, November 7th. The company reported ($0.70) EPS for the quarter, missing the consensus estimate of ($0.53) by ($0.17). The company had revenue of $872.29 million for the quarter. Intelligent Bio Solutions had a negative return on equity of 147.50% and a negative net margin of 288.35%. As a group, equities analysts expect that Intelligent Bio Solutions will post -1.25 earnings per share for the current year.

About Intelligent Bio Solutions

Intelligent Bio Solutions Inc, a medical technology company, developing non-invasive, real-time monitoring, and diagnostic tests for patients and their primary health practitioners. It offers saliva glucose biosensor for diabetes management that measures glucose in saliva. The company also provides intelligent fingerprinting drug screening system, a revolutionizing portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields; and biosensor platform for biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities.